Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
estradiol + estriol + norethindrone
- Development stage
- Unknown
- Lead developer
- Galderma
- Modality
- Small Molecules
- Administration
- Oral, Transdermal, Topical
01
Overview
A combination hormone replacement therapy containing two estrogens (estradiol and estriol) and a progestin (norethindrone). Estradiol is the primary female sex hormone that regulates many processes in the body. Estriol is a weaker form of estrogen. Norethindrone is a synthetic progestin that helps balance the effects of estrogen. This combination would be used to treat menopausal symptoms and prevent osteoporosis in postmenopausal women.
- Other names
- 17-β estradiol + estriol + norethindrone
02
Targets
ESR1 (ERα)ESR2 (ERβ)PR (Progesterone receptor)
Beyond the preview
Go deeper on estradiol + estriol + norethindrone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on estradiol + estriol + norethindrone.